checkAd
    Startseite > Aktien > Outlook Therapeutics > Nachrichten
    Outlook Therapeutics Aktie
    7,5800
     
    USD
    -1,94 %
    -0,1500 USD
    Letzter Kurs 11.05.24 Nasdaq
    7,5500
     
    USD
    1.300 STK
    Geldkurs 10.05.24
    7,5800
     
    USD
    200 STK
    Briefkurs 10.05.24
    ISIN: US69012T3059 · WKN: A4046T · SYM: OTLK · USA

    Neueste Nachrichten

    Outlook Therapeutics Announces Effective Date for 1-for-20 Reverse Stock Split
    12.03.24 · globenewswire · Outlook Therapeutics
    Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update
    14.02.24 · globenewswire · Outlook Therapeutics
    Outlook Therapeutics Doses First Subject in NORSE EIGHT
    31.01.24 · globenewswire · Outlook Therapeutics
    Outlook Therapeutics Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010
    23.01.24 · globenewswire · Outlook Therapeutics
    OTLK DEADLINE TOMORROW: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action – OTLK
    01.01.24 · Business Wire (engl.) · Outlook Therapeutics
    OUTLOOK DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Outlook Therapeutics, Inc. and Encourages Investors to Contact the Firm
    30.12.23 · Business Wire (engl.) · Outlook Therapeutics
    The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Outlook Therapeutics, Inc. (OTLK)
    28.12.23 · Business Wire (engl.) · Outlook Therapeutics
    Outlook Therapeutics Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU
    22.12.23 · globenewswire · Outlook Therapeutics
    Outlook Therapeutics Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010
    19.12.23 · globenewswire · Outlook Therapeutics
    Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Outlook Therapeutics, Inc. (OTLK) Investors
    07.12.23 · Business Wire (engl.) · Outlook Therapeutics
    Outlook Therapeutics Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010
    27.11.23 · globenewswire · Outlook Therapeutics
    OTLK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Outlook Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
    21.11.23 · Business Wire (engl.) · Outlook Therapeutics